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COVID-19: Brief Report
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T

he Theta variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was first
reported in the Central Visayas region, Philippines,
in January 2021. The World Health Organization (WHO)
designated the Theta variant as a variant of interest on
24 March 2021,1 given that it contains the mutations
E484K, which has been associated with antigenic escape;
N501Y, associated with increased transmissibility; and
other mutations of concern found in existing variants of
concern (Tablizo FA, Kim KM, Lapid CM, Castro MJR,
Yangzon MSL, Maralit BA, et al. Philippine Genome
Center, unpublished data, 2021). This report is the first
to describe the epidemiological profile of this variant.
Surveillance for pathogens in the Philippines is
coordinated at the national level by the Department of
Health Epidemiology Bureau and at the regional level by
Regional Epidemiology and Surveillance Units (Regional
Units); surveillance at the local level is conducted by
City and Municipal Epidemiology and Surveillance Units.
Regional Units identify candidates for sequencing among
SARS-CoV-2 specimens that are positive by nucleic
acid amplification test and send these samples to the
Philippine Genome Center for whole-genome sequencing
(WGS). The criteria for sample selection established by
the Central Visayas Regional Unit include specimens
from cases with known travel history from countries with
variants of concern or interest, specimens that are part
of large clusters of positive coronavirus 2019 (COVID-19)
cases and specimens that have a volume >500 µL and
a cycle threshold value <30 (Central Visayas Center for
Health Development, unpublished guidance: collection

and testing guidelines for genomic sequencing, 2021).
To meet the national capacity for WGS, which is about
750 samples weekly,2 the Epidemiology Bureau further
narrows down samples for WGS.
As of 10 June 2021, 950 samples, one sample
per case, had been sent for WGS from the Central
Visayas region, and 321 (33.8%) had been sequenced.
The samples were collected from 30 October 2020 to
16 February 2021. The WGS results were provided to the
Central Visayas Regional Unit between 12 February and
12 March 2021.
Cases were followed up for 60 days post-diagnosis
to determine whether they resolved through clinical recovery or death; clinical recovery was defined as the date
when a case was discharged from a hospital or isolation
facility following SARS-CoV-2 infection. Outcomes were
ascertained based on standard discharge and recovery
criteria as reported by City and Municipal Surveillance
Units or local health facilities.3
Cases were excluded from the analysis if they had
any of the four variants of concern identified as of June
2021 – that is, Alpha, Beta, Gamma or Delta – as these
are known to be associated with higher transmissibility
and mortality. Some specimens were from cases in the
same outbreak cluster or shared the same home address
and date of specimen collection; therefore, all statistical
analyses considered clustering at this level. The risk ratio
(RR) for COVID-19 hospitalization was calculated using
a log-binomial generalized estimating equation with an
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independent working correlation structure and robust
sandwich variance estimator.4 Median recovery times
were calculated from Kaplan–Meier survival curves. The
hazard ratios (HRs) for recovery were estimated using a
shared frailty model, which is an extension of the Cox
proportional hazards model that accounts for clustering,
and the proportional hazards assumption was checked
using Schoenfeld residuals.4 For both RR and HR, the
models were adjusted for morbidity, week of specimen
collection of first positive test, age, sex and province.
Finally, because contact tracing is done by City and
Municipal Surveillance Units, two major cities provided
a copy of their database to the Regional Unit. For cases
with the Theta variant in those cities, close contacts were
counted and cross-referenced with the Regional Unit’s
confirmed COVID-19 line list to determine which close
contacts had tested positive. The secondary attack rate
was calculated as the number of positive close contacts
divided by the total number of close contacts. All analyses were conducted using Stata version 17 (StataCorp,
College Station, TX, USA).
Of the 321 cases with WGS results, four had the
variant of concern and were excluded; thus, the final
sample size was 317 cases, comprising 2.6% of the
12 136 cases confirmed by nucleic acid amplification
tests during the specimen collection period. The Theta
variant was detected in 68 (21.5%) of the samples. For

Table 1.

all cases, most specimens (200/317; 63.1%) and almost
all specimens from Theta variant cases (64/68; 94.1%)
were collected during the first 2 weeks of February
(Table 1). Additionally, most specimens were collected
from cases in Cebu province, including from the independent cities of Cebu City, Lapu-Lapu City and Mandaue City
(191 [60.3%] of specimens overall and 48/68 [70.6%]
among Theta variant cases). The median age of all cases
was 33 years (interquartile range [IQR]: 21–46), and 142
(44.8%) cases occurred among women. The age and sex
distributions were similar between cases with the Theta
and non-Theta variants (Table 1).
Hospitalization was required for 18 of the 68 cases
with the Theta variant (26.5%) compared with 77 of the
249 non-Theta variant cases (30.9%) (data not shown).
The risk for hospitalization was not significantly associated with having the Theta variant (crude RR: 0.86; 95%
confidence interval [CI]: 0.48–1.51; adjusted RR: 0.76;
95% CI: 0.40–1.47) (data not shown). The median time
to recovery was similar, at 17 days, and the HR for recovery also was not associated with the Theta variant (crude
HR: 1.00; 95% CI: 0.70–1.44; adjusted HR: 0.92; 95%
CI: 0.65–1.30) (data not shown). Three cases died, none
of whom had the Theta variant.
Nineteen clusters were identified from two major
cities, with the index case having the Theta variant. The

Comparison of Theta variant and non-Theta variant SARS-CoV-2 cases in the Central Visayas region,
Philippines, 30 October 2020–16 February 2021
Severe acute respiratory syndrome coronavirus 2
Characteristic

All
(N = 317)
a

Theta variant
(N = 68)

Non-Theta variant
(N = 249)

Female, n (%)

142 (44.8)

30 (44.1)

112 (45.0)

Age (years), median (IQR)

33 (21–46)

34.5 (20.5–42)

33 (21–49)

Age group (years), n (%)
0–17

69 (21.8)

15 (22.1)

54 (21.7)

18–44

161 (50.8)

39 (57.3)

122 (49.0)

45–60

53 (16.7)

8 (11.8)

45 (18.1)

34 (10.7)

6 (8.8)

28 (11.2)

191 (60.3)

48 (70.6)

143 (57.4)

200 (63.1)

64 (94.1)

136 (54.6)

>60
In Cebu province, n (%)

b

Specimens collected during the first
2 weeks of February 2021, n (%)c
IQR: interquartile range.
a

Excludes four sequenced samples with variants of concern.

b

A full provincial breakdown is not available due to small sample sizes from some provinces (<5 cases); counts from Cebu province include the independent cities of
Cebu City, Lapu-Lapu City and Mandaue City.

c

Other dates of specimen collection are not available due to small sample sizes in some months (<5 cases).
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median number of close contacts was 8 (IQR: 5–13).
There were 182 close contacts, 81 of whom tested
positive. Therefore, the overall secondary attack rate for
cases infected with the Theta variant was 44.5%.
These preliminary results, showing that the Theta
variant did not seem to be associated with more severe
disease, were similar to findings on the Iota variant
(B.1.526) in New York, which also contained the E484K
mutation.5 Additionally, while the secondary attack rate
was more than twice as high as the 16.6% previously
reported,6 the number of clusters examined was too few
to draw any definitive conclusions. Since March 2021,
most of the country’s biosurveillance capacity has been
dedicated to testing samples from the National Capital
Region and from repatriated Filipinos.7 Further investments to expand biosurveillance capacity, as well as to
facilitate timelier linkages of genomic, epidemiological and
clinical data, may be needed to further understand the
epidemiological profile of the Theta variant. Nonetheless,
our results can contribute to the evidence base used
by WHO and countries affected by the Theta variant to
clarify its status as a variant of interest.
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